A vial and syringe are seen in front of a displayed Pfizer logo in this illustration taken Jan 11, 2021. NEW YORK: Pfizer said on Wednesday its oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalised COVID-19 patients with pneumonia in Brazil, meeting the study's main goal.
Results of the study, which tested the drug in 289 hospitalised adult patients with the respiratory illness caused by the coronavirus, were published in the New England Journal of Medicine.Pfizer said the incidence of death or respiratory failure was 18.1 per cent for patients treated with the drug compared to 29 per cent for placebo. Serious adverse events occurred in 20 patients treated with the drug compared to 17 patients on placebo.
Xeljanz, which belongs to a class of drugs called JAK inhibitors and also treats the autoimmune disease ulcerative colitis, has not been approved or authorized for use in any country for the treatment of COVID-19. Pfizer and German partner BioNTech SE's vaccine is one of the three vaccines currently approved for emergency use in the United States.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: YahooSG - 🏆 3. / 71 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »